Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
Di | P3 Health Partners Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
28.03. | P3 Health stock neutral rating reiterated after earnings miss | 2 | Investing.com | ||
28.03. | P3 Health Partners targets profitability in 2025 with adjusted EBITDA guidance of up to $5M | 1 | Seeking Alpha | ||
13.02. | P3 Health Partners strebt Profitabilität bis 2025 mit Umsatz von bis zu 1,5 Milliarden US-Dollar an | 11 | Investing.com Deutsch | ||
13.02. | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
17.12.24 | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
P3 HEALTH PARTNERS Aktie jetzt für 0€ handeln | |||||
12.11.24 | P3 Health Partners GAAP EPS of -$0.31 misses by $0.27, revenue of $362.1M beats by $2.21M | 4 | Seeking Alpha | ||
12.11.24 | P3 Health Partners Announces Third Quarter 2024 Results | 164 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen | |
12.11.24 | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
07.08.24 | P3 Health Partners Announces Second Quarter 2024 Results | 126 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen | |
08.05.24 | P3 Health Partners Announces First Quarter 2024 Results | 175 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,104 | -2,79 % | Sernova Biotherapeutics Inc: Sernova to continue to Cohort C T1D trial in H2 2025 | ||
ATOSSA THERAPEUTICS | 0,556 | +0,18 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications | SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
PING AN HEALTHCARE | 0,792 | -1,32 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports First Full-Year Profit in 2024 | Synergies Between Health Care and Insurance Drive Scalable GrowthAI Innovations Fuel Continued Success
SHANGHAI and HONG KONG, March 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
MOUNTAIN VALLEY MD | 0,022 | +23,33 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,284 | -1,39 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
CYTOSORBENTS | 0,886 | -1,77 % | Cytosorbents Corp: CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 2024 marked by strong commercial execution and improved operating leverage
Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and... ► Artikel lesen | |
VERU | 0,519 | +0,48 % | Veru Aktie: Kreuzung ohne klare Richtung! | Die Veru-Aktie konnte im jüngsten Handel einen leichten Aufschwung verzeichnen. Am 22. März stieg der Kurs um 2,35% auf 0,48 EUR, was eine positive Entwicklung gegenüber dem Vortagsschluss darstellt.... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 0,588 | +4,53 % | Tempest Therapeutics: Tempest Reports Year End 2024 Financial Results and Provides Business Update | • Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement... ► Artikel lesen | |
VOLITIONRX | 0,560 | 0,00 % | VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada, March 31, 2025 /PRNewswire/ -- VolitionRx... ► Artikel lesen | |
EKSO BIONICS | 0,355 | +0,28 % | Ekso Bionics Holdings Aktie: Beeindruckende Innovationskraft | Der Exoskelett-Hersteller verzeichnet im letzten Quartal 2024 Umsatzsteigerungen und Margenwachstum, kämpft jedoch mit Jahresrückgang bei hoher Aktienvolatilität. Ekso Bionics meldete für das vierte... ► Artikel lesen | |
IMUNON | 0,860 | -2,27 % | Imunon files to sell 10M shares of common stock, warrants | ||
BEYOND AIR | 0,214 | -3,60 % | Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site | ||
AVINGER | 0,340 | -6,08 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
AROVELLA THERAPEUTICS | 0,039 | -2,53 % | AROVELLA THERAPEUTICS LIMITED: Cancel - Proposed issue of securities - ALA | ||
NOVACYT | 0,480 | +5,73 % | Novacyt S.A. - Liquidity Agreement and Total Voting Rights |